Imeglimin may improve albuminuria associated with partial suppression of inflammatory and fibrotic markers in diabetic kidney disease
Yoshimi Muta, Hisashi Yokomizo, Takako Kawanami, Yuriko Hamaguchi, Dai Nagata, Mayuko Yamamoto, Yuki Senda, Yuichi Takashi, Shohta Kodama, Daiji Kawanami · 2026
Read Imeglimin may improve albuminuria associated with partial suppression of inflammatory and fibrotic markers in diabetic kidney disease by Yoshimi Muta, Hisashi Yokomizo, Takako Kawanami, Yuriko Hamaguchi, Dai Nagata, Mayuko Yamamoto, Yuki Senda, Yuichi Takashi, Shohta Kodama, Daiji Kawanami (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13619504.txt.
Description
Yoshimi Muta and nine co-authors test a diabetes drug for kidney protection in a 2026 study with mice and lab cells. The drug, imeglimin, lowers blood sugar and is sold in Japan, but its effect on diabetic kidney disease was unclear. Kidney disease in diabetes shows up early as protein leaking into urine.
In diabetic mice, the drug cut that protein leak without clearly changing blood sugar. Gene checks in kidney tissue showed more activity in protective pathways and less in inflammation and scarring pathways. Scarring in the kidney also fell. In lab cells stressed by high sugar, the drug lowered several harmful signals. The authors suggest the drug helps the kidney in part by calming inflammation.
Catalog record
| CREATOR | Yoshimi Muta, Hisashi Yokomizo, Takako Kawanami, Yuriko Hamaguchi, Dai Nagata, Mayuko Yamamoto, Yuki Senda, Yuichi Takashi, Shohta Kodama, Daiji Kawanami |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |